Acute acalculous cholecystitis due to hepatitis B virus reactivation: A case report and review of the literature.

We report a 52-year old man presenting with acute acalculous cholecystitis triggered by hepatitis B virus infection. The patient developed protective antibodies and cleared the infection. The relevant data is also discussed.

Long-term effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection.

INTRODUCTION: Several studies have reported that interferon therapy increases elimination rate of HBeAg and anti-HBe seroconversion in chronic hepatitis B (CHB) patients. We aimed to evaluate long-term results of interferon-α treatment in HBeAg positive CHB patients in a country with exclusively D genotype. METHODS: Seventy-one naive CHB patients (M/F 61/10, mean age 29±12 years, range 16-62) treated with 6 months of interferon-α 2b, 10 MU tiw and had a consequent untreated follow-up period of at least 10 years with positive response were identified and their data were reviewed. The therapy response was defined as HBeAg seroconversion with undetectable HBV-DNA. The responders were followed-up at 3-6-month intervals. RESULTS: Twenty-eight (39%) patients achieved HBeAg seroconversion (25 within the therapy, 3 within the consequent 12 months off-treatment follow-up). The responders were followed-up with a mean period of 152 months (range 123-181). In the follow-up period, 21/25 (84%) initial responders relapsed. On the other hand, 3 patients who did not respond at the end of therapy sustained the response during follow-up. Hence 21/28 total responders relapsed (75%), either with HBeAg reversion (3, 14.3%) or HBV-DNA elevation over 2000 IU/ml (or its equivalent in other types of definitions) and ALT elevation (18, 85.7%). The sustained response was present in 7 patients (9.8%). Serious side effects precluding completion of treatment occurred in three patients (4.2%). In multivariate analysis none of the pre-treatment parameters appeared to be significant in predicting response. CONCLUSION: Sustained response to interferon treatment is low in HBeAg positive CHB patients with genotype D.

Electrocardiographical P wave changes after electroconvulsive therapy in patients with schizophrenia: a preliminary study.

OBJECTIVE: Cardiac ventricular conduction has been studied in patients with schizophrenia who have undergone electroconvulsive therapies while they were drug-naive or drug-free or on drug regimens; however, atrial conduction has not been studied in this setting. We aimed to measure atrial and ventricular conduction changes in hospitalized patients with schizophrenia after convulsive therapy. METHODS: Fifteen people with schizophrenia and 15 healthy people enrolled in the study. The participants were assessed for fasting blood glucose and electrolyte levels before the study. All patients were receiving atypical antipsychotics. The electrocardiography records were obtained before the first convulsive therapy and after the third session. RESULTS: The baseline P minimum duration in the patient group was significantly smaller than healthy controls. There was a significant increase in patients' P maximum duration after the third convulsive therapy session (P < 0.05). The differences in P Wave Dispersion, QTc, and QT Dispersion between baseline and after the third session in patients were not statistically significant (P > 0.05). CONCLUSIONS: The lower P wave duration minimum may be related to autonomic nervous system dysregulation in schizophrenia because an acute episode of the illness and/or antipsychotic drugs. In addition, we propose that electroconvulsive therapy alone or in combination with atypical antipsychotics may influence atrial conduction as evidenced by the significantly prolonged P wave maximum.